MedPath
HSA Approval

OBUTIN TABLETS 5 mg

SIN11215P

OBUTIN TABLETS 5 mg

OBUTIN TABLETS 5 mg

November 4, 1999

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

G04BD04

oxybutynin

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

HANLIM PHARMACEUTICAL CO LTD

Active Ingredients

OXYBUTYNIN CHLORIDE

5 mg

Oxybutynin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

OBUTIN TABLETS 5 mg - HSA Approval | MedPath